ABILIFY XTENIM Trademark

Trademark Overview

On Thursday, November 1, 2012, a trademark application was filed for ABILIFY XTENIM with the United States Patent and Trademark Office. The USPTO has given the ABILIFY XTENIM trademark a serial number of 79121973. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Wednesday, November 2, 2022. This trademark is owned by Otsuka Pharmaceutical Co., Ltd.. The ABILIFY XTENIM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of central nervous system diseases and disorders
abilify xtenim

General Information

Serial Number79121973
Word MarkABILIFY XTENIM
Filing DateThursday, November 1, 2012
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateWednesday, November 2, 2022
Registration Number4381792
Registration DateTuesday, August 13, 2013
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, May 28, 2013

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of central nervous system diseases and disorders
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, February 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOTSUKA PHARMACEUTICAL CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 101-8535
JP
Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 101-8535
JP

Trademark Events

Event DateEvent Description
Monday, May 22, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, May 22, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Sunday, May 21, 2023DEATH OF INTERNATIONAL REGISTRATION
Sunday, April 24, 2022TOTAL INVALIDATION PROCESSED BY THE IB
Friday, March 18, 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Friday, March 18, 2022INVALIDATION PROCESSED
Tuesday, October 26, 2021TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, February 26, 2021CANCELLED SECTION 71
Monday, August 13, 2018COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, August 28, 2014CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, December 9, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, November 15, 2013FINAL DISPOSITION NOTICE SENT TO IB
Thursday, November 14, 2013FINAL DISPOSITION PROCESSED
Wednesday, November 13, 2013FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 13, 2013REGISTERED-PRINCIPAL REGISTER
Tuesday, May 28, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 28, 2013PUBLISHED FOR OPPOSITION
Wednesday, May 8, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 25, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, April 23, 2013ASSIGNED TO LIE
Monday, April 8, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, April 6, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 5, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 5, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 25, 2013REFUSAL PROCESSED BY IB
Friday, March 1, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, March 1, 2013REFUSAL PROCESSED BY MPU
Friday, March 1, 2013NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, February 28, 2013NON-FINAL ACTION WRITTEN
Tuesday, February 26, 2013ASSIGNED TO EXAMINER
Tuesday, January 1, 2013APPLICATION FILING RECEIPT MAILED
Friday, December 28, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 21, 2012LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, December 20, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

xtenim abilify system diseases disorders nervous central preparations treatment prevention pharmaceutical